Ablative radiotherapy for liver tumors using stereotactic MRI-guidance: A prospective phase I trial

•SBRT using MR-Co is a safe and feasible option for treatment of liver tumors with ablative doses.•2-year LC with MRgRT is comparable to prior series using a conventional CT-guided linear accelerator.•A difference in LC between number of lesions (single vs. multiple) and BED (< or ≥100 Gy) was ob...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Radiotherapy and oncology 2022-05, Vol.170, p.14-20
Hauptverfasser:	van Dams, Ritchell, Wu, Trudy C., Kishan, Amar U., Raldow, Ann C., Chu, Fang-I, Hernandez, Jackie, Cao, Minsong, Lamb, James M., Mikaeilian, Argin, Low, Daniel A., Steinberg, Michael L., Lee, Percy
Format:	Artikel
Sprache:	eng
Schlagworte:	Ablative radiotherapy Clinical trial Humans Liver Neoplasms - diagnostic imaging Liver Neoplasms - radiotherapy Liver tumors Magnetic Resonance Imaging - methods MR-guided Prospective Studies Radiosurgery - methods Radiotherapy, Image-Guided - adverse effects Radiotherapy, Image-Guided - methods
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	•SBRT using MR-Co is a safe and feasible option for treatment of liver tumors with ablative doses.•2-year LC with MRgRT is comparable to prior series using a conventional CT-guided linear accelerator.•A difference in LC between number of lesions (single vs. multiple) and BED (< or ≥100 Gy) was observed.•MR-guided SBRT is very well tolerated without any acute grade 3 toxicities.•V35Gy 1000 cc or >800 cc of normal liver receiving
ISSN:	0167-8140 1879-0887
DOI:	10.1016/j.radonc.2021.06.005